For the Inventor, By the Inventor

Enter assignee name

Sunnyvale, CA, United States of America

Pharmacyclics, Inc.

USPTO Granted Patents = 194

% Expired Patents = 6.7

CIPO Patents = 7

EPO Patents = 24

Trademarks = 7

Forward Citations = 6,306

Loading Chart...

Loading Chart...

113 inventors (with patents filed for the assignee):

Erik J Verner (67 out of 83 patents)

Lee Honigberg (53 out of 53 patents)

Joseph J Buggy (48 out of 51 patents)

4. David J Loury (44 out of 46 patents)

5. Tarak D Mody (39 out of 54 patents)

6. Zhengying Pan (39 out of 39 patents)

7. Wei Yu Chen (29 out of 128 patents)

8. Jonathan L Sessler (26 out of 89 patents)

9. Darren Magda (24 out of 39 patents)

10. Norbert Purro (19 out of 19 patents)

11. Sriram Balasubramanian (15 out of 16 patents)

12. Mark Stephen Smyth (14 out of 41 patents)

13. Laurence Elias (13 out of 16 patents)

14. Erick A Goldman (13 out of 25 patents)

15. David Dale Wirth (13 out of 30 patents)

Core Competencies:

Bruton's Tyrosine Kinase

Kinase Inhibitors

Pharmaceutical Formulations

Crystalline Forms

Solid Tumors

Fibrosis Treatment

Histone Deacetylase

Adjuvant Therapy

Resistance Mutations

194 patents: Sort by Forward Citations

1. 12551448 - Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor (2026-02-17),

2. 11672803 - Use of inhibitors of Brutons tyrosine kinase (Btk) (2023-06-13),

3. 10961251 - Crystalline forms of a Bruton's tyrosine kinase inhibitor (2021-03-30),

4. 10954567 - Mutations associated with resistance to inhibitors of Bruton's Tyrosine Kinase (BTK) (2021-03-23),

5. 10898461 - Salts of 3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl) phenoxy]ethyli-1-benzofuran-2-carboxamide, related crystalline forms, method for preparing the same and pharmaceutical compositions containing the same (2021-01-26),

6. 10828259 - Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor (2020-11-10),

7. 10752634 - Crystalline forms of a brutons tyrosine kinase inhibitor (2020-08-25),

8. 10751342 - Use of inhibitors of Bruton's tyrosine kinase (Btk) (2020-08-25),

9. 10695350 - Methods of treating and preventing graft versus host disease (2020-06-30),

10. 10653696 - Use of inhibitors of bruton's tyrosine kinase (BTK) (2020-05-19),

11. 10478439 - Use of inhibitors of bruton's tyrosine kinase (Btk) (2019-11-19),

12. 10463668 - Methods of treating and preventing graft versus host disease (2019-11-05),

13. 10294232 - Crystalline forms of a Bruton's tyrosine kinase inhibitor (2019-05-21),

14. 10294231 - Crystalline forms of a Bruton's tyrosine kinase inhibitor (2019-05-21),

15. 10266540 - Crystalline forms of a Bruton's tyrosine kinase inhibitor (2019-04-23),

Pharmacyclics, Inc., based in Sunnyvale, California, specializes in the development of innovative therapies targeting Bruton's Tyrosine Kinase (BTK) for the treatment of various cancers and fibrotic diseases. The company focuses on creating kinase inhibitors and pharmaceutical formulations that enhance treatment efficacy for solid tumors and other conditions. With a strong emphasis on research and development, Pharmacyclics aims to advance therapeutic options that improve patient outcomes in oncology and related fields.

Profile summary based on public USPTO records.

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

Pharmacyclics, Inc.

194 Patents

#28 in Sunnyvale, CA

#464 in California

#2,125 in US

#4,346 in the World

Sunnyvale, CA, United States of America

Pharmacyclics, Inc.

Forward Citations = 6,306

113 inventors:

Erik J Verner (67 out of 83 patents)

Lee Honigberg (53 out of 53 patents)

Joseph J Buggy (48 out of 51 patents)

4. David J Loury (44 out of 46 patents)

5. Tarak D Mody (39 out of 54 patents)

Please report any incorrect information to [email protected]

Loading…